Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Medicenna Presents Data on MDNA11, an IL-2 Superkine at ASCO 2020 | ||
By: PR Newswire Association LLC. - 29 May 2020 | Back to overview list |
|
-MDNA11, a long acting IL-2 super-agonist shows potent and durable tumor control with strong memory response in tumor models- TORONTO, May 29, 2020 /PRNewswire/ - Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company, today announced virtual presentation of data on MDNA11, one of its lead candidates from the IL-2 Superkine program, at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. The poster presentation by Dr. Moutih Rafei, PhD, (Associate Professor of Pharmacology and Physiology at the University de Montreal) focuses on new data arising from MDNA11, Medicenna's novel long-acting interleukin-2 (IL-2) Superkine program. "Recent transactions in the immuno-oncology and IL-2 space are evidence of the industry demand for drug candidates that can effectively boost the immune system of patients undergoing cancer treatment. The data we are sharing at ASCO show that MDNA11 has the potential to be a best-in-class IL-2 asset," says Dr. Fahar Merchant, Chief Executive Officer, Medicenna. "We are impressed by MDNA11's preclinical profile, including its selectivity for immune effector cells, pharmacokinetics, safety and preclinical efficacy. We look forward to progressing MDNA11 towards the clinic in the next 12 months and to share these data with the ASCO community." The poster presentation focuses on encouraging data in NHP for MDNA11, a long-acting IL-2 variant engineered to have enhanced affinity to CD122 without interacting with CD25. This allows MDNA11 to specifically expand cancer fighting naïve CD8 T cells as well as natural killer (NK) cells with minimal stimulation of T regulatory cells (Tregs) and eosinophils (associated with vascular leak syndrome). As such, the use of MDNA11 circumvents both immune-suppression and toxicity normally observed with standard IL-2 (Proleukin). In addition, MDNA11 has several advantages over other long-acting IL-2 variants as it permits enhanced accumulation in the tumor vicinity and can be recycled in vivo thus exhibiting prolonged circulation in the blood stream thereby reducing the frequency of treatment. Highlights from the presentation include:
About Medicenna Therapeutics Corp. This news release contains forward-looking statements relating to the future operations of the Company and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects", "believes" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements related to that MDNA11 has the potential to be a best-in-class IL-2 asset, that the Company will progress MDNA11 towards the clinic in the next 12 months and the future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the risks detailed in the annual information form of the Company dated May 14, 2020 and in other filings made by the Company with the applicable securities regulators from time to time. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect and that study results could change over time as the study is continuing to follow up all patients and new data are continually being received which could materially change study results. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements only as expressly required by Canadian securities law. View original content:http://www.prnewswire.com/news-releases/medicenna-presents-data-on-mdna11-an-il-2-superkine-at-asco-2020-301067658.html SOURCE Medicenna Therapeutics Corp. |
||
|
||
Copyright 2020 PR Newswire Association LLC. | Back to overview list |